Technology Management

Two implantable cardioverter defibrillator (ICD) systems made by Biotronik were approved by the U.S. Food and Drug Administration, the company announced July 19.

Mountain View, California-based AliveCor, which makes the personal electrocardiogram, Kardia Mobile, has plans to enhance the device with a new detection feature through a collaboration with Mayo Clinic.

Because liver transplants are among the surgeries at the highest risk to cause cardiac problems, researchers at Northwestern Medicine in Chicago have developed an app that can predict a liver transplant patient’s one-year risk of dying or being hospitalized due to a heart attack or other cardiac event.

According to a new study, pacemakers and other cardiac devices could help solve forensic cases by revealing a person’s time and cause of death where an autopsy can’t.

St. Louis-based Stereotaxis, a cardiac technology maker, launched its e-Contact module in Europe last week, bringing a device to market that can significantly ease the jobs of cardiologists.

Dublin-based Medtronic revealed encouraging results from a study completed on its Micra Transcatheter Pacing System (TPS), which showed a 99.6 percent implant success rate and low chances of major complications occurring.

Abbott announced its smartphone-compatible insertable cardiac monitor (ICM) has gained CE Mark. The device allows physicians to remotely monitor patients, potentially diagnosing arrhythmias and atrial fibrillation (AFib).

Just last week, Lake Oswego, Oregon-based Biotronik announced that two of its new products, the SentusProMRI and its MultiPole Pacing technology, were approved by the U.S. Food and Drug Administration (FDA). This week at the annual Heart Rhythm Society conference in Chicago, the company showed off the new devices.

Abiomed has debuted the third generation of its Impella CP heart pump, a device designed to unload the heart and let it naturally recover. 

Biotronik’s Sentus ProMRI, a thin quadripolar left ventricular lead, has been approved by the U.S. Food and Drug Administration (FDA), the company announced today.

In an effort to reduce and prevent the incidence of heart disease, researchers in Europe have developed a new tool that designs personalized workouts for patients at risk or living with the condition.

Biomedical technology company Biotronik has launched the smallest MR-conditional tachycardia lead available in the U.S.